Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis

被引:14
作者
Benzerdjeb, Nazim [1 ]
Dartigues, Peggy [2 ]
Kepenekian, Vahan [3 ]
Valmary-Degano, Severine [4 ]
Mery, Eliane [5 ]
Averous, Gerlinde [6 ]
Chevallier, Anne [7 ]
Laverriere, Marie-Helene [4 ]
Villa, Irene [2 ]
Harou, Olivier [1 ]
Salle, Francoise Galateau [8 ]
Villeneuve, Laurent [9 ]
Glehen, Olivier [3 ]
Isaac, Sylvie [1 ]
Hommell-Fontaine, Juliette [1 ]
Bibeau, Frederic [10 ]
机构
[1] Hosp Civils Lyon, Grp Hosp Sud Hosp, Inst Pathol Multisite, Dept Pathol, Pierre Benite, France
[2] Gustave Roussy Inst, Dept Pathol, Villejuif, France
[3] Lyon Univ Hosp, Dept Digest Surg, F-69000 Lyon, France
[4] Grenoble Univ Hosp, Dept Pathol, Grenoble, France
[5] IUTC Oncopole, Claudius Regaud Inst, Dept Pathol, Toulouse, France
[6] CHU Strasbourg, Dept Pathol, Strasbourg, France
[7] CHU Archet II, Dept Pathol, Nice, France
[8] MESOPATH, Ctr Leon Berard, Dept Biopathol, Lyon, France
[9] Hosp Civils Lyon, Pole Sante Publ, Serv Epidemiol & Rech Clin, Lyon, France
[10] Univ Caen Normandie, Caen Univ Hosp, Dept Pathol, Caen, France
关键词
Malignant epithelioid peritoneal mesothelioma; Biomarker; Mesothelioma; Tertiary lymphoid structures; SYSTEMIC CHEMOTHERAPY; TUMORS;
D O I
10.1007/s00428-021-03099-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant peritoneal mesothelioma. The relationship between a strong adaptive immune response and a better prognosis in malignant solid tumors is widely known. Due to the low incidence of epithelioid malignant peritoneal mesothelioma (EMPM), very little is known about their immune micro-environment. We encountered several cases of tertiary lymphoid structures in EMPM in a previous study and aimed to investigate in the same series the prevalence, clinicopathological features, and the prognostic impact associated with tertiary lymphoid structures in EMPM (TLS-EMPM). Cases of EMPM, from 1995 to 2018, were retrieved from 7 French institutions from the RENAPE Network. The predictions in terms of overall survival (OS) and progression-free survival (PFS) of TLS-EMPM were analyzed. We report 52 cases of TLS-EMPM among a series of 138 cases of EMPM. TLS-EMPM was significantly associated with neoadjuvant chemotherapy, and was not a prognostic indicator for OS (p = 0.652) and PFS (p = 0.804) in our series. TLS is a component of the host immune response to EMPM significantly associated with neoadjuvant chemotherapy, but was not a predictor of prognosis for overall and progression-free survivals in this series. These findings provide another possible etiology for tertiary lymphoid structures.
引用
收藏
页码:765 / 772
页数:8
相关论文
共 26 条
[1]   Malignant peritoneal mesothelioma in women - A study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis [J].
Baker, PM ;
Clement, PB ;
Young, RH .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (05) :724-737
[2]   Malignant peritoneal mesothelioma and Crohn disease [J].
Butnor, Kelly J. ;
Pavlisko, Elizabeth N. ;
Sporn, Thomas A. ;
Roggli, Victor L. .
JOURNAL OF CLINICAL PATHOLOGY, 2017, 70 (03) :228-232
[3]   The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy [J].
Chu, Gerard J. ;
van Zandwijk, Nico ;
Rasko, John E. J. .
FRONTIERS IN ONCOLOGY, 2019, 9
[4]   The Role of Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy [J].
Deraco, Marcello ;
Baratti, Dario ;
Hutanu, Ionut ;
Bertuli, Rossella ;
Kusamura, Shigeki .
ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (04) :1093-1100
[5]   The immune contexture in human tumours: impact on clinical outcome [J].
Fridman, Wolf Herman ;
Pages, Franck ;
Sautes-Fridman, Catherine ;
Galon, Jerome .
NATURE REVIEWS CANCER, 2012, 12 (04) :298-306
[6]   Stromal tumour-infiltrating lymphocytes (TILs) assessed using the ITWG system do not predict overall survival in a cohort of 337 cases of mesothelioma [J].
Fuchs, Talia L. ;
Chou, Angela ;
Sioson, Loretta ;
Sheen, Amy ;
Gill, Anthony J. .
HISTOPATHOLOGY, 2020, 76 (07) :1095-1101
[7]  
Glehen O, MESOTHELIOME PERITON
[8]  
GRAHAM DM, 1990, MODERN PATHOL, V3, P332
[9]   Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics [J].
Hato, Stanleyson V. ;
Andrea Khong ;
de Vries, I. Jolanda M. ;
Lesterhuis, W. Joost .
CLINICAL CANCER RESEARCH, 2014, 20 (11) :2831-2837
[10]   Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group [J].
Husain, Aliya Noor ;
Colby, Thomas V. ;
Ordonez, Nelson G. ;
Allen, Timothy Craig ;
Attanoos, Richard Luther ;
Beasley, Mary Beth ;
Butnor, Kelly Jo ;
Chirieac, Lucian R. ;
Churg, Andrew M. ;
Dacic, Sanja ;
Galateau-Salle, Francoise ;
Gibbs, Allen ;
Gown, Allen M. ;
Krausz, Thomas ;
Litzky, Leslie Anne ;
Marchevsky, Alberto ;
Nicholson, Andrew G. ;
Roggli, Victor Louis ;
Sharma, Anupama K. ;
Travis, William D. ;
Walts, Ann E. ;
Wick, Mark R. .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (01) :89-108